Loading news...
RARE resubmits FDA filing for UX111 after CRL, adding long-term neurologic and biomarker data, with a Q3 2026 decision in sight.
Nurix Therapeutics (NASDAQ: NRIX - Get Free Report) and Ultragenyx Pharmaceutical (NASDAQ: RARE - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Analyst Ratings This is a summary of recent
Company expects up to six-month review period per FDA guidelines New longer-term clinical data demonstrating durable positive brain biochemical and clinical effect for as long as 8.5 years to be presented at WORLDSymposium™ 2026 NOVATO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has resubmitted its Biologics License Application (BLA) seeking accelerated approval for UX111 (rebisufligene etisparvovec) AAV9 gene therapy as a treatment for patients with Sanfilippo syndrome type A (MPS IIIA) to the U.S. Food and Drug Administration (FDA or the Agency).
NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Ultragenyx Pharmaceutical (NASDAQ: RARE - Get Free Report) and Denali Therapeutics (NASDAQ: DNLI - Get Free Report) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk. Risk and Volatility Ultragenyx Pharmaceutical has a
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
New York, New York--(Newsfile Corp. - January 26, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Ultragenyx Pharmaceutical Inc. ("Ultragenyx Pharmaceutical Inc.") (NASDAQ: RARE) concerning potential violations of the federal securities laws. Ultragenyx reported the study results on December 29, 2025.
NOVATO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 16,355 restricted stock units of the company's common stock to nine newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of January 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
NEW YORK, Jan. 23, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) following the Company's announcement of topline results from its Phase III Orbit and Cosmic Studies, focusing on the effectiveness of setrusumab (UX143) on Osteogenesis Imperfecta. Investors with concerns about Ultragenyx's business operations may click here for more information.
THIS NEWS RELEASEIS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / January 22, 2026 / Tactical Resources Corp. (TSXV:RARE)(OTC PINK:USREF) ("Tactical" or the "Company"), a mineral exploration and development company, is pleased to announce the closing of its previously announced non-brokered private placement of 207,625 common shares of the Company (the "Shares") at an issue price of $6.30 per Share, for gross proceeds of $1,308,037.50 (the "Offering"). The securities issued pursuant to the Offering are subject to a statutory hold period of four (4) months plus a day from the date of issuance in accordance with applicable securities legislation.
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Ultragenyx is rated BUY with a $55 price target, offering 145% implied upside after a sharp post-trial selloff. RARE's commercial base, anchored by Crysvita and Dojolvi, provides a robust revenue safety net, with 2025 guidance above consensus and 20% projected annual growth. Key pipeline catalysts include GTX-102 Phase 3 data (Angelman's, H2 2025), GSDIa BLA submission, and Sanfilippo Syndrome Type A BLA resubmission, all with high success probabilities.
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ("Ultragenyx Pharmaceutical Inc.") concerning potential violations of the federal securities laws. What Happened?
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Ultragenyx Pharmaceutical Inc. ("Ultragenyx Pharmaceutical Inc.") (NASDAQ: RARE) concerning potential violations of the federal securities laws. What Happened?
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Ultragenyx Pharmaceutical Inc. (RARE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Preliminary 2025 total revenue of $672 million to $674 million, exceeding top end of guidance Preliminary cash and investments of approximately $735 million as of December 31, 2025 Anticipated 2026 catalysts include two potential approvals and pivotal Phase 3 data from the GTX-102 Phase 3 Aspire study for Angelman syndrome
SG Americas Securities LLC purchased a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 125,429 shares of the biopharmaceutical company's stock, valued at approximately $3,773,000. SG Americas Securities LLC owned